GLENMARK2,403.10

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹67,815 Cr
Holding % of Total Shares
12 Months Ending
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Promoter & Group46.6446.6546.6546.6546.6546.6546.6546.6546.6546.65
FII / FPI21.3820.9823.0523.5123.1620.6220.7319.2020.3420.89
DII13.3613.9213.2113.8514.6017.6418.6120.0919.2918.60
Mutual Funds10.5510.9211.4112.1212.8615.5516.3117.8616.8016.76
Latest: 2026-06-30 · 59 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.